Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Small molecule-directed immunotherapy against recurrent infection by Mycobacterium tuberculosis.

Bhattacharya D, Dwivedi VP, Maiga M, Maiga M, Van Kaer L, Bishai WR, Das G.

J Biol Chem. 2014 Jun 6;289(23):16508-15. doi: 10.1074/jbc.M114.558098. Epub 2014 Apr 7.

2.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
3.

Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene.

Changhong S, Hai Z, Limei W, Jiaze A, Li X, Tingfen Z, Zhikai X, Yong Z.

Tuberculosis (Edinb). 2009 Jan;89(1):54-61. doi: 10.1016/j.tube.2008.09.005. Epub 2008 Dec 3.

PMID:
19056317
5.

Human in vitro immune responses to Mycobacterium tuberculosis.

Wilsher ML, Hagan C, Prestidge R, Wells AU, Murison G.

Tuber Lung Dis. 1999;79(6):371-7.

PMID:
10694982
7.

Protective and therapeutic effects of the resuscitation-promoting factor domain and its mutants against Mycobacterium tuberculosis in mice.

Zhao S, Song X, Zhao Y, Qiu Y, Mao F, Zhang C, Bai B, Zhang H, Wu S, Shi C.

Pathog Dis. 2015 Apr;73(3). pii: ftu025. doi: 10.1093/femspd/ftu025. Epub 2015 Jan 5.

PMID:
25743472
8.

Protective efficacy of piperine against Mycobacterium tuberculosis.

Sharma S, Kalia NP, Suden P, Chauhan PS, Kumar M, Ram AB, Khajuria A, Bani S, Khan IA.

Tuberculosis (Edinb). 2014 Jul;94(4):389-96. doi: 10.1016/j.tube.2014.04.007. Epub 2014 May 9.

PMID:
24880706
9.

Rapid rebound of the Treg compartment in DEREG mice limits the impact of Treg depletion on mycobacterial burden, but prevents autoimmunity.

Berod L, Stüve P, Varela F, Behrends J, Swallow M, Kruse F, Krull F, Ghorbani P, Mayer CT, Hölscher C, Sparwasser T.

PLoS One. 2014 Jul 22;9(7):e102804. doi: 10.1371/journal.pone.0102804. eCollection 2014.

10.

Development of mixed Th1/Th2 type immune response and protection against Mycobacterium tuberculosis after rectal or subcutaneous immunization of newborn and adult mice with Mycobacterium bovis BCG.

Lagranderie M, Balazuc AM, Abolhassani M, Chavarot P, Nahori MA, Thouron F, Milon G, Marchal G.

Scand J Immunol. 2002 Mar;55(3):293-303.

11.

IL-22 is mainly produced by IFNγ-secreting cells but is dispensable for host protection against Mycobacterium tuberculosis infection.

Behrends J, Renauld JC, Ehlers S, Hölscher C.

PLoS One. 2013;8(2):e57379. doi: 10.1371/journal.pone.0057379. Epub 2013 Feb 27.

12.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
14.

Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice.

Wu J, Ma H, Qu Q, Zhou WJ, Luo YP, Thangaraj H, Lowrie DB, Fan XY.

Vaccine. 2011 Oct 13;29(44):7624-30. doi: 10.1016/j.vaccine.2011.08.020. Epub 2011 Aug 19.

PMID:
21856352
15.

Th1/Th2 balance in infection.

Infante-Duarte C, Kamradt T.

Springer Semin Immunopathol. 1999;21(3):317-38. Review.

PMID:
10666776
17.

Protective CD4 T cells targeting cryptic epitopes of Mycobacterium tuberculosis resist infection-driven terminal differentiation.

Woodworth JS, Aagaard CS, Hansen PR, Cassidy JP, Agger EM, Andersen P.

J Immunol. 2014 Apr 1;192(7):3247-58. doi: 10.4049/jimmunol.1300283. Epub 2014 Feb 26.

18.
19.

Th1-specific bystander costimulation imparts resistance against Mycobacterium tuberculosis infection.

Das G, Vohra H, Saha B, Mishra GC.

Scand J Immunol. 2000 Nov;52(5):515-8.

20.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602

Supplemental Content

Support Center